Overcoming therapeutic inertia in patients with hypertension

Area of Science:

• Cardiology
• Hypertension Management
• Clinical Trials

Background:

• Uncontrolled blood pressure (BP) is a major global cause of cardiovascular disease and mortality.
• Current hypertension treatment guidelines are not consistently implemented, leading to poor BP control in real-world practice compared to clinical trials.
• Therapeutic inertia, or the failure to adjust treatment, is a significant barrier to achieving BP goals.

Purpose of the Study:

• To discuss the issue of therapeutic inertia in hypertension management.
• To highlight the disparity in BP control rates between clinical trials and clinical practice.
• To provide the rationale for a treat-to-goal study using amlodipine/olmesartan medoxomil combination therapy.

Main Methods:

• Review of current practice guidelines and clinical trial data.
• Discussion of therapeutic inertia and its impact on hypertension control.
• Description of a treat-to-goal study design for inadequately controlled hypertension.

Main Results:

• Clinical practice shows significantly lower BP control rates than clinical trials.
• Therapeutic inertia is a key factor contributing to suboptimal BP control.
• Aggressive treatment strategies, including initial combination therapy, are being explored.

Conclusions:

• Addressing therapeutic inertia is crucial for improving hypertension management.
• Fixed-dose combination therapy, such as amlodipine/olmesartan medoxomil, shows promise for achieving BP goals.
• Further research and implementation strategies are needed to enhance BP control rates globally.